Skip to main content
Top
Published in: Cancer Causes & Control 12/2015

01-12-2015 | Original paper

Associations between sociodemographic and clinicopathological factors and breast cancer subtypes in a population-based study

Authors: Adana A. M. Llanos, Sheenu Chandwani, Elisa V. Bandera, Kim M. Hirshfield, Yong Lin, Christine B. Ambrosone, Kitaw Demissie

Published in: Cancer Causes & Control | Issue 12/2015

Login to get access

Abstract

Purpose

This study examines the factors distinguishing breast cancer (BC) subtypes.

Methods

We examined subtypes in 629 women with invasive BC, diagnosed from 2006 to 2012, and enrolled in an epidemiological study in New Jersey. Using molecular characteristics from pathology reports, BCs were categorized as luminal A, luminal B, non-luminal HER2-expressing, or triple-negative breast cancer (TNBC) subtypes. Multinomial logistic models (luminal A as referent) were used to describe BC subtype associations.

Results

Women with luminal B tumors were more likely to be younger at diagnosis [odds ratio (OR) 1.8, 95 % confidence interval (CI) 1.0–3.4] and to have higher-grade (OR 2.6, 95 % CI 1.5–4.7), larger (OR 1.9, 95 % CI 1.0–3.6), and Ki67-positive tumors (OR 2.1, 95 % CI 1.1–4.0). Women with non-luminal HER2-expressing BCs were more likely to have higher-grade tumors (OR 14.5, 95 % CI 5.3–39.7). Women with TNBCs were more likely to be African-American (OR 1.9, 95 % CI 1.0–3.4) and to have higher-grade (OR 9.7, 95 % CI 5.1–18.4), larger (OR 2.2, 95 % CI 1.0–4.8), and Ki67-positive (OR 2.9, 95 % CI 1.6–5.2) tumors. Notably, compared to the luminal A subtype, luminal B, non-luminal HER2-expressing, and triple-negative subtypes were more frequently self-detected; however, these associations were attenuated in multivariable models.

Conclusions

These findings suggest that some BC subtypes were associated with features denoting more aggressive phenotypes, namely higher grade, larger size, and Ki67 positivity, and possibly patient self-detection among some women. These findings highlight a need for enhanced screening, particularly among younger women, racial/ethnic minorities, and lower socioeconomic subgroups.
Literature
1.
go back to reference Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. doi:10.1038/35021093 CrossRefPubMed Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. doi:10.​1038/​35021093 CrossRefPubMed
2.
go back to reference Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874. doi:10.1073/pnas.191367098 PubMedCentralCrossRefPubMed Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874. doi:10.​1073/​pnas.​191367098 PubMedCentralCrossRefPubMed
3.
go back to reference Bastien RR, Rodriguez-Lescure A, Ebbert MT, Prat A, Munarriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Alvarez I, Dowell T, Wall D, Segui MA, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Anton A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martin M (2012) PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics 5:44. doi:10.1186/1755-8794-5-44 PubMedCentralCrossRefPubMed Bastien RR, Rodriguez-Lescure A, Ebbert MT, Prat A, Munarriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Alvarez I, Dowell T, Wall D, Segui MA, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Anton A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martin M (2012) PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics 5:44. doi:10.​1186/​1755-8794-5-44 PubMedCentralCrossRefPubMed
5.
go back to reference Sweeney C, Bernard PS, Factor RE, Kwan ML, Habel LA, Quesenberry CP Jr, Shakespear K, Weltzien EK, Stijleman IJ, Davis CA, Ebbert MT, Castillo A, Kushi LH, Caan BJ (2014) Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomark Prev 23(5):714–724. doi:10.1158/1055-9965.EPI-13-1023 CrossRef Sweeney C, Bernard PS, Factor RE, Kwan ML, Habel LA, Quesenberry CP Jr, Shakespear K, Weltzien EK, Stijleman IJ, Davis CA, Ebbert MT, Castillo A, Kushi LH, Caan BJ (2014) Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomark Prev 23(5):714–724. doi:10.​1158/​1055-9965.​EPI-13-1023 CrossRef
6.
go back to reference Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, Dabbs DJ (2009) Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol 2(5):444–455PubMedCentralPubMed Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, Dabbs DJ (2009) Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol 2(5):444–455PubMedCentralPubMed
7.
go back to reference Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10(4):R67. doi:10.1186/bcr2128 PubMedCentralCrossRefPubMed Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10(4):R67. doi:10.​1186/​bcr2128 PubMedCentralCrossRefPubMed
9.
go back to reference Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J Am Med Assoc 295(21):2492–2502. doi:10.1001/jama.295.21.2492 CrossRef Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J Am Med Assoc 295(21):2492–2502. doi:10.​1001/​jama.​295.​21.​2492 CrossRef
10.
go back to reference Sineshaw HM, Gaudet M, Ward EM, Flanders WD, Desantis C, Lin CC, Jemal A (2014) Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010–2011). Breast Cancer Res Treat 145(3):753–763. doi:10.1007/s10549-014-2976-9 CrossRefPubMed Sineshaw HM, Gaudet M, Ward EM, Flanders WD, Desantis C, Lin CC, Jemal A (2014) Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010–2011). Breast Cancer Res Treat 145(3):753–763. doi:10.​1007/​s10549-014-2976-9 CrossRefPubMed
13.
go back to reference Kroenke CH, Sweeney C, Kwan ML, Quesenberry CP, Weltzien EK, Habel LA, Castillo A, Bernard PS, Factor RE, Kushi LH, Caan BJ (2014) Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression. Breast Cancer Res Treat 144(3):689–699. doi:10.1007/s10549-014-2899-5 PubMedCentralCrossRefPubMed Kroenke CH, Sweeney C, Kwan ML, Quesenberry CP, Weltzien EK, Habel LA, Castillo A, Bernard PS, Factor RE, Kushi LH, Caan BJ (2014) Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression. Breast Cancer Res Treat 144(3):689–699. doi:10.​1007/​s10549-014-2899-5 PubMedCentralCrossRefPubMed
14.
go back to reference Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomaki K, Heikkila P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, Humphreys K, Darabi H, Liu J, Van ‘t Veer LJ, van Leeuwen FE, Andrulis IL, Glendon G, Knight JA, Mulligan AM, O’Malley FP, Weerasooriya N, John EM, Beckmann MW, Hartmann A, Weihbrecht SB, Wachter DL, Jud SM, Loehberg CR, Baglietto L, English DR, Giles GG, McLean CA, Severi G, Lambrechts D, Vandorpe T, Weltens C, Paridaens R, Smeets A, Neven P, Wildiers H, Wang X, Olson JE, Cafourek V, Fredericksen Z, Kosel M, Vachon C, Cramp HE, Connley D, Cross SS, Balasubramanian SP, Reed MW, Dork T, Bremer M, Meyer A, Karstens JH, Ay A, Park-Simon TW, Hillemanns P, Arias Perez JI, Menendez Rodriguez P, Zamora P, Benitez J, Ko YD, Fischer HP, Hamann U, Pesch B, Bruning T, Justenhoven C, Brauch H, Eccles DM, Tapper WJ, Gerty SM, Sawyer EJ, Tomlinson IP, Jones A, Kerin M, Miller N, McInerney N, Anton-Culver H, Ziogas A, Shen CY, Hsiung CN, Wu PE, Yang SL, Yu JC, Chen ST, Hsu GC, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Lindblom A, Margolin S, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Gorski B, Gronwald J, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A, Kriege M, Tilanus-Linthorst MM, Collee M, Wang-Gohrke S, Pylkas K, Jukkola-Vuorinen A, Mononen K, Grip M, Hirvikoski P, Winqvist R, Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Auvinen P, Soini Y, Sironen R, Bojesen SE, Orsted DD, Kaur-Knudsen D, Flyger H, Nordestgaard BG, Holland H, Chenevix-Trench G, Manoukian S, Barile M, Radice P, Hankinson SE, Hunter DJ, Tamimi R, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gaborieau V, Devilee P, Huijts PE, Tollenaar RA, Seynaeve C, Dite GS, Apicella C, Hopper JL, Hammet F, Tsimiklis H, Smith LD, Southey MC, Humphreys MK, Easton D, Pharoah P, Sherman ME, Garcia-Closas M (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103(3):250–263. doi:10.1093/jnci/djq526 Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomaki K, Heikkila P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, Humphreys K, Darabi H, Liu J, Van ‘t Veer LJ, van Leeuwen FE, Andrulis IL, Glendon G, Knight JA, Mulligan AM, O’Malley FP, Weerasooriya N, John EM, Beckmann MW, Hartmann A, Weihbrecht SB, Wachter DL, Jud SM, Loehberg CR, Baglietto L, English DR, Giles GG, McLean CA, Severi G, Lambrechts D, Vandorpe T, Weltens C, Paridaens R, Smeets A, Neven P, Wildiers H, Wang X, Olson JE, Cafourek V, Fredericksen Z, Kosel M, Vachon C, Cramp HE, Connley D, Cross SS, Balasubramanian SP, Reed MW, Dork T, Bremer M, Meyer A, Karstens JH, Ay A, Park-Simon TW, Hillemanns P, Arias Perez JI, Menendez Rodriguez P, Zamora P, Benitez J, Ko YD, Fischer HP, Hamann U, Pesch B, Bruning T, Justenhoven C, Brauch H, Eccles DM, Tapper WJ, Gerty SM, Sawyer EJ, Tomlinson IP, Jones A, Kerin M, Miller N, McInerney N, Anton-Culver H, Ziogas A, Shen CY, Hsiung CN, Wu PE, Yang SL, Yu JC, Chen ST, Hsu GC, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Lindblom A, Margolin S, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Gorski B, Gronwald J, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A, Kriege M, Tilanus-Linthorst MM, Collee M, Wang-Gohrke S, Pylkas K, Jukkola-Vuorinen A, Mononen K, Grip M, Hirvikoski P, Winqvist R, Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Auvinen P, Soini Y, Sironen R, Bojesen SE, Orsted DD, Kaur-Knudsen D, Flyger H, Nordestgaard BG, Holland H, Chenevix-Trench G, Manoukian S, Barile M, Radice P, Hankinson SE, Hunter DJ, Tamimi R, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gaborieau V, Devilee P, Huijts PE, Tollenaar RA, Seynaeve C, Dite GS, Apicella C, Hopper JL, Hammet F, Tsimiklis H, Smith LD, Southey MC, Humphreys MK, Easton D, Pharoah P, Sherman ME, Garcia-Closas M (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103(3):250–263. doi:10.​1093/​jnci/​djq526
15.
go back to reference Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart M (2014) Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol 32(25):2794–2803. doi:10.1200/JCO.2013.54.1870 CrossRefPubMed Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart M (2014) Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol 32(25):2794–2803. doi:10.​1200/​JCO.​2013.​54.​1870 CrossRefPubMed
16.
go back to reference Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM (2013) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31(2):203–209. doi:10.1200/JCO.2012.43.4134 PubMedCentralCrossRefPubMed Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM (2013) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31(2):203–209. doi:10.​1200/​JCO.​2012.​43.​4134 PubMedCentralCrossRefPubMed
17.
go back to reference Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750. doi:10.1093/jnci/djp082 PubMedCentralCrossRefPubMed Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750. doi:10.​1093/​jnci/​djp082 PubMedCentralCrossRefPubMed
19.
go back to reference Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortes J, Parker JS, Perou CM, Baselga J (2014) Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst. doi:10.1093/jnci/dju152 Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortes J, Parker JS, Perou CM, Baselga J (2014) Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst. doi:10.​1093/​jnci/​dju152
21.
go back to reference Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368–1376. doi:10.1158/1078-0432.CCR-07-1658 CrossRefPubMed Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368–1376. doi:10.​1158/​1078-0432.​CCR-07-1658 CrossRefPubMed
22.
go back to reference Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167. doi:10.1200/JCO.2008.18.1370 PubMedCentralCrossRefPubMed Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167. doi:10.​1200/​JCO.​2008.​18.​1370 PubMedCentralCrossRefPubMed
23.
go back to reference Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, Bernstein L, Enger SM, Press MF (2012) Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomark Prev 21(10):1848–1855. doi:10.1158/1055-9965.EPI-12-0474 CrossRef Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, Bernstein L, Enger SM, Press MF (2012) Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomark Prev 21(10):1848–1855. doi:10.​1158/​1055-9965.​EPI-12-0474 CrossRef
24.
go back to reference Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes FA, O’Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai L (2011) Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 103(3):264–272. doi:10.1093/jnci/djq524 CrossRefPubMed Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes FA, O’Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai L (2011) Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 103(3):264–272. doi:10.​1093/​jnci/​djq524 CrossRefPubMed
25.
go back to reference George P, Chandwani S, Gabel M, Ambrosone CB, Rhoads G, Bandera EV, Demissie K (2015) Diagnosis and surgical delays in African American and white women with early-stage breast cancer. J Womens Health (Larchmt). doi:10.1089/jwh.2014.4773 George P, Chandwani S, Gabel M, Ambrosone CB, Rhoads G, Bandera EV, Demissie K (2015) Diagnosis and surgical delays in African American and white women with early-stage breast cancer. J Womens Health (Larchmt). doi:10.​1089/​jwh.​2014.​4773
26.
go back to reference Ambrosone CB, Ciupak GL, Bandera EV, Jandorf L, Bovbjerg DH, Zirpoli G, Pawlish K, Godbold J, Furberg H, Fatone A, Valdimarsdottir H, Yao S, Li Y, Hwang H, Davis W, Roberts M, Sucheston L, Demissie K, Amend KL, Tartter P, Reilly J, Pace BW, Rohan T, Sparano J, Raptis G, Castaldi M, Estabrook A, Feldman S, Weltz C, Kemeny M (2009) Conducting molecular epidemiological research in the age of HIPAA: a multi-institutional case–control study of breast cancer in African-American and European-American women. J Oncol 2009:871250. doi:10.1155/2009/871250 PubMedCentralCrossRefPubMed Ambrosone CB, Ciupak GL, Bandera EV, Jandorf L, Bovbjerg DH, Zirpoli G, Pawlish K, Godbold J, Furberg H, Fatone A, Valdimarsdottir H, Yao S, Li Y, Hwang H, Davis W, Roberts M, Sucheston L, Demissie K, Amend KL, Tartter P, Reilly J, Pace BW, Rohan T, Sparano J, Raptis G, Castaldi M, Estabrook A, Feldman S, Weltz C, Kemeny M (2009) Conducting molecular epidemiological research in the age of HIPAA: a multi-institutional case–control study of breast cancer in African-American and European-American women. J Oncol 2009:871250. doi:10.​1155/​2009/​871250 PubMedCentralCrossRefPubMed
28.
go back to reference Sarode VR, Han JS, Morris DH, Peng Y, Rao R (2011) A comparative analysis of biomarker expression and molecular subtypes of pure ductal carcinoma in situ and invasive breast carcinoma by image analysis: relationship of the subtypes with histologic grade, Ki67, p53 overexpression, and DNA ploidy. Int J Breast Cancer 2011:217060. doi:10.4061/2011/217060 PubMedCentralCrossRefPubMed Sarode VR, Han JS, Morris DH, Peng Y, Rao R (2011) A comparative analysis of biomarker expression and molecular subtypes of pure ductal carcinoma in situ and invasive breast carcinoma by image analysis: relationship of the subtypes with histologic grade, Ki67, p53 overexpression, and DNA ploidy. Int J Breast Cancer 2011:217060. doi:10.​4061/​2011/​217060 PubMedCentralCrossRefPubMed
29.
go back to reference de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96(10):1504–1513. doi:10.1038/sj.bjc.6603756 de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96(10):1504–1513. doi:10.​1038/​sj.​bjc.​6603756
31.
go back to reference Zhang GC, Qian XK, Guo ZB, Ren CY, Yao M, Li XR, Wang K, Zu J, Liao N (2012) Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients. Med Oncol 29(5):3222–3231. doi:10.1007/s12032-012-0242-8 CrossRefPubMed Zhang GC, Qian XK, Guo ZB, Ren CY, Yao M, Li XR, Wang K, Zu J, Liao N (2012) Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients. Med Oncol 29(5):3222–3231. doi:10.​1007/​s12032-012-0242-8 CrossRefPubMed
32.
go back to reference Kashiwagi S, Yashiro M, Takashima T, Aomatsu N, Ikeda K, Ogawa Y, Ishikawa T, Hirakawa K (2011) Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Res 13(6):R122. doi:10.1186/bcr3068 PubMedCentralCrossRefPubMed Kashiwagi S, Yashiro M, Takashima T, Aomatsu N, Ikeda K, Ogawa Y, Ishikawa T, Hirakawa K (2011) Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Res 13(6):R122. doi:10.​1186/​bcr3068 PubMedCentralCrossRefPubMed
33.
go back to reference Niikura N, Masuda S, Kumaki N, Xiaoyan T, Terada M, Terao M, Iwamoto T, Oshitanai R, Morioka T, Tuda B, Okamura T, Saito Y, Suzuki Y, Tokuda Y (2014) Prognostic significance of the Ki67 scoring categories in breast cancer subgroups. Clin Breast Cancer 14(5):323–329; e323. doi:10.1016/j.clbc.2013.12.013 Niikura N, Masuda S, Kumaki N, Xiaoyan T, Terada M, Terao M, Iwamoto T, Oshitanai R, Morioka T, Tuda B, Okamura T, Saito Y, Suzuki Y, Tokuda Y (2014) Prognostic significance of the Ki67 scoring categories in breast cancer subgroups. Clin Breast Cancer 14(5):323–329; e323. doi:10.​1016/​j.​clbc.​2013.​12.​013
34.
go back to reference Sueta A, Yamamoto Y, Hayashi M, Yamamoto S, Inao T, Ibusuki M, Murakami K, Iwase H (2014) Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: Is it equally useful across tumor subtypes? Surgery 155(5):927–935. doi:10.1016/j.surg.2014.01.009 CrossRefPubMed Sueta A, Yamamoto Y, Hayashi M, Yamamoto S, Inao T, Ibusuki M, Murakami K, Iwase H (2014) Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: Is it equally useful across tumor subtypes? Surgery 155(5):927–935. doi:10.​1016/​j.​surg.​2014.​01.​009 CrossRefPubMed
38.
go back to reference Domingo L, Blanch J, Servitja S, Corominas JM, Murta-Nascimento C, Rueda A, Redondo M, Castells X, Sala M (2013) Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers. Eur J Cancer Prev 22(1):21–28. doi:10.1097/CEJ.0b013e328354d324 CrossRefPubMed Domingo L, Blanch J, Servitja S, Corominas JM, Murta-Nascimento C, Rueda A, Redondo M, Castells X, Sala M (2013) Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers. Eur J Cancer Prev 22(1):21–28. doi:10.​1097/​CEJ.​0b013e328354d324​ CrossRefPubMed
40.
go back to reference Roth MY, Elmore JG, Yi-Frazier JP, Reisch LM, Oster NV, Miglioretti DL (2011) Self-detection remains a key method of breast cancer detection for U.S. women. J Womens Health (Larchmt) 20(8):1135–1139. doi:10.1089/jwh.2010.2493 CrossRef Roth MY, Elmore JG, Yi-Frazier JP, Reisch LM, Oster NV, Miglioretti DL (2011) Self-detection remains a key method of breast cancer detection for U.S. women. J Womens Health (Larchmt) 20(8):1135–1139. doi:10.​1089/​jwh.​2010.​2493 CrossRef
41.
go back to reference Crispo A, Barba M, D’Aiuto G, De LaurentiisM, Grimaldi M, Rinaldo M, Caolo G, D’Aiuto M, Capasso I, Esposito E, Amore A, Di BonitoM, Botti G, Montella M (2013) Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series. BMC Cancer 13:15. doi:10.1186/1471-2407-13-15 PubMedCentralCrossRefPubMed Crispo A, Barba M, D’Aiuto G, De LaurentiisM, Grimaldi M, Rinaldo M, Caolo G, D’Aiuto M, Capasso I, Esposito E, Amore A, Di BonitoM, Botti G, Montella M (2013) Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series. BMC Cancer 13:15. doi:10.​1186/​1471-2407-13-15 PubMedCentralCrossRefPubMed
44.
go back to reference Wang Y, Yin Q, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y (2011) A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat 130(2):489–498. doi:10.1007/s10549-011-1709-6 CrossRefPubMed Wang Y, Yin Q, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y (2011) A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat 130(2):489–498. doi:10.​1007/​s10549-011-1709-6 CrossRefPubMed
45.
go back to reference Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, Greenberg DC, Pharoah P, Caldas C, Wishart GC (2009) Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 101(8):1338–1344. doi:10.1038/sj.bjc.6605317 PubMedCentralCrossRefPubMed Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, Greenberg DC, Pharoah P, Caldas C, Wishart GC (2009) Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 101(8):1338–1344. doi:10.​1038/​sj.​bjc.​6605317 PubMedCentralCrossRefPubMed
46.
go back to reference Kim J, Lee S, Bae S, Choi MY, Lee J, Jung SP, Kim S, Choe JH, Kim JH, Kim JS, Lee JE, Nam SJ, Yang JH (2012) Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes. Breast Cancer Res Treat 131(2):527–540. doi:10.1007/s10549-011-1836-0 CrossRefPubMed Kim J, Lee S, Bae S, Choi MY, Lee J, Jung SP, Kim S, Choe JH, Kim JH, Kim JS, Lee JE, Nam SJ, Yang JH (2012) Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes. Breast Cancer Res Treat 131(2):527–540. doi:10.​1007/​s10549-011-1836-0 CrossRefPubMed
47.
go back to reference Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA (2005) Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 97(16):1195–1203. doi:10.1093/jnci/dji239 CrossRefPubMed Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA (2005) Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 97(16):1195–1203. doi:10.​1093/​jnci/​dji239 CrossRefPubMed
48.
go back to reference Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J (2004) Risk for distant recurrence of breast cancer detected by mammography screening or other methods. J Am Med Assoc 292(9):1064–1073. doi:10.1001/jama.292.9.1064 CrossRef Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J (2004) Risk for distant recurrence of breast cancer detected by mammography screening or other methods. J Am Med Assoc 292(9):1064–1073. doi:10.​1001/​jama.​292.​9.​1064 CrossRef
Metadata
Title
Associations between sociodemographic and clinicopathological factors and breast cancer subtypes in a population-based study
Authors
Adana A. M. Llanos
Sheenu Chandwani
Elisa V. Bandera
Kim M. Hirshfield
Yong Lin
Christine B. Ambrosone
Kitaw Demissie
Publication date
01-12-2015
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 12/2015
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-015-0667-4

Other articles of this Issue 12/2015

Cancer Causes & Control 12/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine